NCE-1 Intelligence & Market Opportunity

Verquvo

Vericiguat

Cardiovascular agent

Oral Tablet

Approval Date

19-Jan-21

NCE-1 Date

19-Jan-25

NCE Date

19-Jan-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

312

2027

382

2028

451

2029

535

2030

617

2031

697

2032

778

Molecule profile

Details & specifications

Molecule

Vericiguat

Innovator

MERCK SHARP & DOHME LLC

Dosage Form

Oral Tablet

Strength

5 mg, 10 mg, 2.5 mg

Therapeutic Category

Cardiovascular agent

Usage

To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.